深圳开立生物医疗科技股份有限公司

What 深圳开立生物医疗科技股份有限公司 does

SonoScape Medical Corporation (深圳开立生物医疗科技股份有限公司, Shenzhen Stock Exchange: 300633) is a publicly traded Chinese medical device company founded in 2002 by Yao Jinzhong, a pioneer of ultrasound medicine in China. The company develops, manufactures, and sells diagnostic imaging and therapeutic equipment across five business lines: ultrasound medical imaging (flagship color Doppler systems S80/河图 and P80/梦溪 plus portable X11, E11, E10, X5 lines), endoscopy diagnosis and treatment (iEndo next-generation platform, HD-550/580, ultrasound endoscopy EG-UC5T and EG-UR5, EU-10 micro-probe, bronchoscopes, and consumables), minimally invasive surgery (SV-M4K40, 凌珠 4K 3D fluorescence endoscopic imaging), cardiovascular intervention (V-reader V10 IVUS, SonoSound 60MHz diagnostic catheter), and veterinary solutions (ProPet series). The product architecture is organized around proprietary intelligent platforms — Wis+, Aurora/极光, C-Field+/天工, and iEndo — that share imaging pipelines across price tiers.

The company generates revenue primarily through hardware sales of medical imaging and endoscopy equipment, supplemented by recurring endoscopy consumables (biopsy forceps, snares, ERCP/EMR/ESD categories, hemostatic clips) and professional services (after-sales support, training, remote consultation). 2025 consolidated revenue was 2.309 billion CNY with net profit of 197 million CNY attributable to shareholders. Go-to-market combines direct field sales via more than 30 domestic regional offices, a nationwide distributor and channel network, event-driven academic marketing (CMEF, Chinese Medical Association conferences, the '开立杯' national endoscopy case competition), and clinical research partnerships with top-tier hospitals (Shengjing Hospital, Guangzhou Medical University First Affiliated Hospital, Southern Medical University Shenzhen Hospital). Internationally, the company pursues Belt-and-Road country expansion and now holds EU CE (MDR) certification for its ultrasound electronic bronchoscopy system (first domestic Chinese product of its kind in the EU) and IVUS product line. Approximately 20% of annual revenue is reinvested into R&D, supporting an 800+ person R&D organization of which 55% hold master's or doctoral degrees.

The company's core customer base is Chinese public hospitals — spanning tier-3 academic centers, tier-2 general hospitals, and grassroots clinics — alongside emerging international hospital and veterinary accounts. Ownership is concentrated among co-founders Chen Zhiqiang (Chairman, 22.12%) and Wu Kunxiang (Director/GM, 22.12%), who jointly control the listed entity together with VP Huang Yibo (4.65%). The company has positioned itself as a domestic substitute for imported high-end medical devices, with AI-integrated screening (S-Fetus 凤眼, predictive auto-measurement modules), high-frequency intravascular imaging, and 4K fluorescence endoscopy as its main differentiators.

Name

深圳开立生物医疗科技股份有限公司

Legal name

深圳开立生物医疗科技股份有限公司

Website

https://sonoscape.com.cn

Company type

Public

Founded year

2002

Operating status

Operating

Headcount range

101–250 employees

Short description

SonoScape Medical Corporation is a publicly listed Chinese medical device company (300633) that develops and manufactures ultrasound, endoscopy, minimally invasive surgery, cardiovascular intervention, and veterinary equipment with AI-integrated imaging platforms, serving public hospitals in China and select international markets.

Ownership category

akta.pro rank

Product category

Medical Imaging Equipment

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation) (HLAHADAB)

akta.pro secondary industries

Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA), Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN), Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits) (HLAHADAM), Imaging Equipment & Accessories (X-ray, Ultrasound, Endoscopy) (HLAMAFAC)

Keywords

• Medical imaging equipment
• Ultrasound diagnostic systems
• Endoscopy equipment
• Cardiovascular intervention devices
• Veterinary ultrasound systems

Headquarters

HQ city

深圳

Offices14 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. 医疗设备销售（超声、内镜、微创外科、心血管介入、动物医疗设备）: 开立医疗核心收入来源，通过销售彩色多普勒超声诊断系统、电子内窥镜系统、超声内镜系统、超声内窥镜摄像系统、血管内超声成像系统、动物专用超声等医疗设备整机产品获取收入。2025年营业收入23.09亿元。
2. 内镜耗材及周边设备: 公司生产和销售内镜周边设备（送气装置、送水装置）及耗材（活检钳、圈套器、止血夹、ERCP类、EMR/ESD类耗材等），作为设备销售的补充收入来源。
3. 专业服务及技术支持: 通过提供售后服务、技术培训、远程会诊系统等增值服务获取收入。

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

深圳开立生物医疗科技股份有限公司 (SonoScape) develops, manufactures, and sells medical imaging and minimally invasive medical devices across five product lines: ultrasound medical imaging systems (from portable to ultra-high-end flagship), endoscopy diagnosis and treatment systems (including electronic endoscopy, ultrasound endoscopy, and bronchoscopy), minimally invasive surgical imaging platforms (4K fluorescence endoscopy), cardiovascular intervention devices (intravascular ultrasound/IVUS), and veterinary ultrasound/endoscopy solutions. The company also sells related endoscopy consumables and provides after-sales service and technical training.

Product overview

SonoScape Medical Corporation (深圳开立生物医疗科技股份有限公司) offers a comprehensive medical imaging portfolio comprising five major product lines: Ultrasound Medical Imaging (超声医学影像), Endoscopy Diagnosis & Treatment (内镜诊疗), Minimally Invasive Surgery (微创外科), Cardiovascular Intervention (心血管介入), and Animal Medical Solutions (动物医疗). The product portfolio includes high-end flagship ultrasound systems (S80/河图, P80/梦溪), portable ultrasound systems (X10, E10, E11, X11), advanced endoscopy platforms (iEndo, HD-580, HD-550), ultrasound endoscopic systems (EG-UC5T, EG-UR5, EU-10), intravascular ultrasound systems (V-reader V10, SonoSound), 4K fluorescence laparoscopic systems (SV-M4K40, 凌珠系列), and specialized veterinary ultrasound and endoscopy solutions (ProPet series). AI-powered features include the 凤眼 TMS-Fetus intelligent obstetric screening system with automated measurements and intelligent worklow assistants across product lines. The company operates a platform-plus-modules architecture with proprietary intelligent platforms (Wis+, Aurora/极光, C-Field+/天工) powering differentiated product tiers from premium flagship to entry-level systems.

Differentiator

Problem solved

Functional benefit

Brands

• 河图®: 超高端旗舰超声产品系列品牌，搭载先进场成像发射、自适应聚合重建等核心技术。
• 梦溪®
• 凤眼 TMS-Fetus®
• V-reader®
• SonoSound®
• SonoHelp
• Sono-Trans
• 智联Expert
• SonoShare / 智联Show
• Sono-Report
• ProPet
• 凌珠®系列
• 精卫®系列
• iEndo
• SFI 聚谱成像技术
• VIST 光电复合染色成像技术
• HCI 融合光谱成像技术
• ICE 复合图像增强技术
• μ-Scan 微米成像
• C-Field+® 天工平台
• 极光平台
• Wis+ 平台

Products and services

• S80/河图 (Hē tú) Ultra-High-End Color Doppler Ultrasound System

Quantifiable outcome

• AI辅助产筛：单例检查时间缩短（725.0s vs 871.0s），测量完整率提升12.1%，切面完整率提升11.2%
• +2 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature9 records

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Philips Healthcare: Major incumbent in ultrasound (EPIQ, Affiniti), image-guided therapy, and patient monitoring. Comparable breadth across hospital departments; SonoScape targets Philips's lower-tier ultrasound accounts for displacement.
• Boston Scientific: Global IVUS leader (OPTICROSS, AVVIGO) and cardiovascular intervention incumbent. SonoScape's 60MHz IVUS catheter and V-reader V10 imaging system compete for the same interventional cardiology catheter lab budgets.
• GE HealthCare: Global ultrasound leader (LOGIQ, Voluson, Vivid series) and broader imaging incumbent. SonoScape competes in the mid-tier ultrasound segment and increasingly in women's-health, where GE's Voluson has long been entrenched.
• Siemens Healthineers: Ultrasound (ACUSON) and broader imaging portfolio with strong cardiovascular focus — directly comparable segment overlap with SonoScape's X11 portable cardiovascular ultrasound. Also active in IVUS via historical Corindus adjacency.

Direct peers

• Mindray (迈瑞医疗): China's largest medical device company with material overlap in ultrasound imaging (Resona/Ie Elite series), patient monitoring, and in-vitro diagnostics. Direct competitor in Chinese public-hospital ultrasound tenders where SonoScape also bids aggressively.
• Pentax Medical (Hoya Corporation): Direct competitor in flexible endoscopy (gastrointestinal and bronchoscopy) with the i10 and EB-J series. SonoScape's electronic bronchoscopy CE(MDR) certification specifically targets the same EU procurement accounts Pentax relies on.
• Karl Storz: German endoscopy specialist, particularly strong in rigid and 3D/4K laparoscopy. Overlap is material on SonoScape's 凌珠 series 4K 3D fluorescence endoscopy platform targeting minimally invasive surgery departments.
• Aohua Endoscopy (澳华内镜): Another Shanghai-listed Chinese flexible endoscopy specialist (AQ-300, VIST-Like staining). Most direct domestic competitor in SonoScape's HD-550/HD-580 gastrointestinal endoscopy tier; frequent co-bidder in Chinese county- and tier-2 hospital tenders.
• Fujifilm Healthcare: Competes head-to-head in both endoscopy systems (ELUXEO) and diagnostic ultrasound (ARIETTA/FC1 series). Comparable product breadth and similarly aggressive push into AI-assisted imaging; a directly analogous business mix to SonoScape.
• Olympus Corporation: Global leader in flexible endoscopy and the dominant incumbent SonoScape targets with its HD-550/HD-580/iEndo platforms. Overlap is direct on gastrointestinal endoscopy systems, bronchoscopy, and endoscopic accessories across hospital departments worldwide.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/%E6%B7%B1%E5%9C%B3%E5%BC%80%E7%AB%8B%E7%94%9F%E7%89%A9%E5%8C%BB%E7%96%97%E7%A7%91%E6%8A%80%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B8

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 深圳开立生物医疗科技股份有限公司